A randomised controlled trial of antenatal melatonin supplementation in fetal growth restriction for fetal neuroprotection.
A triple-blind, randomized, parallel-group, placebo controlled trial to assess the impact of maternal antenatal melatonin supplementation on early childhood neurodevelopmental outcomes in the setting of severe preterm fetal growth restriction.
Monash Health
336 participants
May 30, 2019
Interventional
Conditions
Summary
During pregnancy, fetal growth restriction (FGR) is a recognised causal pathway to neurodevelopmental injury, which manifests, following birth, as cognitive and behavioural impairment as well as cerebral palsy. Currently, antenatal care is focused on detecting FGR and assessment of fetal wellbeing to guide timing of delivery. This approach seeks to maximize gestational age at birth to minimise the risks of prematurity, while delivering the fetus in time to minimise the likelihood of stillbirth. However, no therapies exist that can maximize fetal wellbeing in the setting of FGR and minimise the frequency of antenatally acquired brain injury. This double-blind RCT seeks to recruit n=332 women with FGR pregnancies to determine if antenatal maternal Melatonin administration can PROTECT the fetal brain and lead to improved neurodevelopmental outcomes.
Eligibility
Inclusion Criteria10
- Women, with a singleton pregnancy
- Severe fetal growth restriction (FGR), defined as:
- Estimated fetal weight equal to, or less than, 3rd centile for gestational age according to charts from Mikolajczyk et al (2011) or an estimated fetal weight that is less than the 10th centile (Mikolajcyk et al 2011) in combination with at least one abnormal fetoplacental doppler study, these being:
- Uterine artery (raised pulsatility index equal to, or more than, 95th centile)
- Umbilical artery (pulsatility index equal to, or more than, 95th centile or absent/reversed end-diastolic flow)
- Ductus venosus (abnormal A wave and/or pulsatility index equal to, or more than, 95th centile)
- Gestation: (confirmed) 23+0 to 31+6 weeks’
- Age: 18 years or more
- Understands English
- Reference: Mikolajczyk, R.T., et al., A global reference for fetal-weight and birthweight percentiles. Lancet, 2011. 377 (9780): pp. 1855-61
Exclusion Criteria3
- A fetus with a known chromosomal, major structural anomaly or non-placental cause of fetal growth restriction
- Pregnancies requiring immediate delivery (eg absent A wave in ductus venosus, preterminal CTG or biophysical profile)
- Co-recruitment in another clinical trial where a pharmaceutical product or nutritional supplement is the trial intervention.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The intervention for this trial is: melatonin (10mg) -the dose administered, 10mg three times daily (tds) - the duration of administration: from the time of recruitment to the trial until birth - the mode of administration: oral tablet
Locations(14)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12617001515381